

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that the Group is expected to record a substantial reduction in profit for the six months ended 30 June 2017 as compared to the profit for the same period in 2016.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Common Splendor International Health Industry Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record a reduction of approximately 70% in profit before tax for the six months ended 30 June 2017 as compared to the profit before tax for the corresponding period in 2016 of HK\$41.5 million. Such reduction in profit for the six months ended 30 June 2017 was mainly attributable to (i) the substantial increase of finance costs of approximately HK\$12.8 million arising from the issue of convertible notes, guaranteed notes and bonds by the Company; and (ii) the absence of a one-off gain on disposal of an associate as compared to the corresponding period in 2016, where the Group recorded a gain on disposal of an associate of HK\$28.6 million.

The information contained in this announcement is only based on the preliminary assessment by the Board based on the information currently available to the Company, including the management accounts of the Group, which has neither been reviewed by the audit committee of the Board nor reviewed or audited by the external auditors of the Company. Further details of the Group's financial performance will be disclosed when the Company finalises and announces its financial results for the six months ended 30 June 2017, which is currently expected to be published on 30 August 2017.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 10 August 2017

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kaiwen as non-executive Directors; and Mr. Mai Yang Guang and Mr. Lam Chi Wing as independent non-executive Directors.